In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

The replacement of the Omicron BA.1 variant of SARS-CoV-2 by the BA.2 and the rapid growth of the BA.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the European Union. Using clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Touret, Franck, Baronti, Cécile, Pastorino, Boris, Villarroel, Paola Mariela Saba, Ninove, Laetitia, Nougairède, Antoine, de Lamballerie, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308029/
https://www.ncbi.nlm.nih.gov/pubmed/35871089
http://dx.doi.org/10.1038/s41598-022-16964-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308029/
https://www.ncbi.nlm.nih.gov/pubmed/35871089
http://dx.doi.org/10.1038/s41598-022-16964-z

Ejemplares similares